How to assess the clinical benefit of anticancer drug therapy regimens and allocate the budget?
Authors: N.M. Volkov
DOI: https://www.doi.org/10.31917/2503191
Cancer drug therapy is rapidly developing but even more rapid are the rising expenditures for innovative cancer drugs. Since the budget for cancer care is rising but still finite, robust approaches are needed which can help to prioritize the choice of more efficient drugs and spend the budget with maximal benefit for cancer patients. This lecture gives a brief overview of existing approaches to the assessment and comparison of clinical and economic efficacy of innovative cancer drugs with their advantages and deficiencies and the unmet need in this field.